ReviewJournal of the Chinese Medical Association : JCMA2026
Artificial intelligence in advanced liver disease: From risk stratification to decision.
Review in Journal of the Chinese Medical Association : JCMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis and management of liver cirrhosis and portal hypertension have been challenging for hundreds of years, placing a tremendous burden on medical and social resources. In routine practice, clinicians usually depend on various documented scoring and stratification systems to establish the diagnosis and make decisions. These systems have traditionally been constructed through manual review of retrospective data, image interpretation, and statistical analyses. However, the development of artificial intelligence (AI) has allowed for the analysis of large and varied datasets, and consequently the ability to identify novel factors and test the predictive power of different combinations of factors that would not be feasible using traditional means. Considering the promise of using AI for research in this notorious disease entity, this review article discusses recent advances in AI technology regarding various clinical aspects of liver cirrhosis and portal hypertension. Topics covered include the diagnosis of cirrhosis and clinically significant portal hypertension, detection and prediction of major cirrhosis-related complications (gastroesophageal varices, hepatic encephalopathy, infection, acute kidney injury, hepatorenal syndrome, and hepatocellular carcinoma), assessing the prognosis, and evaluating the treatment response. The potential benefits, drawbacks, limitations, and future perspectives of AI are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.